Madrigal Pharmaceuticals, Inc. (MDGL)

$284.49

+1.03

(+0.36%)

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $276.63
    $289.91
    $284.49
    downward going graph

    2.76%

    Downside

    Day's Volatility :4.58%

    Upside

    1.87%

    downward going graph
  • $119.76
    $299.98
    $284.49
    downward going graph

    57.9%

    Downside

    52 Weeks Volatility :60.08%

    Upside

    5.16%

    downward going graph

Returns

PeriodMadrigal Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
46.62%
6.5%
0.0%
6 Months
25.44%
7.1%
0.0%
1 Year
40.79%
9.8%
0.0%
3 Years
231.84%
14.2%
-20.2%

Highlights

Market Capitalization
6.1B
Book Value
$41.13
Earnings Per Share (EPS)
-23.14
PEG Ratio
0.0
Wall Street Target Price
365.33
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-40.13%
Return On Equity TTM
-88.78%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-453.6M
Diluted Eps TTM
-23.14
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-27.94
EPS Estimate Next Year
-17.78
EPS Estimate Current Quarter
-6.28
EPS Estimate Next Quarter
-6.61

Analyst Recommendation

Buy
    80%Buy
    14%Hold
    4%Sell
Based on 21 Wall street analysts offering stock ratings for Madrigal Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 21 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
17
17
16
Hold
3
3
3
Sell
1
00
00

Analyst Forecast

What analysts predicted

Upside of 28.42%

Current $284.49
Target $365.33

Technicals Summary

Sell

Neutral

Buy

Madrigal Pharmaceuticals, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc.
2.94%
25.44%
40.79%
231.84%
235.85%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc.
NA
NA
0.0
-27.94
-0.89
-0.4
NA
41.13
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc.
Buy
$6.1B
235.85%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Madrigal Pharmaceuticals, Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 20.8%

Institutional Holdings

  • HHG PLC

    12.21%
  • Baker Bros Advisors LP

    9.24%
  • venBio Select Advisor LLC

    9.12%
  • Paulson & Company Inc

    8.33%
  • Vanguard Group Inc

    7.83%
  • BlackRock Inc

    5.68%

Corporate Announcements

  • Madrigal Pharmaceuticals, Inc. Earnings

    Madrigal Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

madrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.

Organization
Madrigal Pharmaceuticals, Inc.
Employees
376
CEO
Dr. Rebecca A. Taub M.D.
Industry
Health Technology

FAQs